Searched over 200M research papers
10 papers analyzed
These studies suggest that valsartan acts by reducing oxidative stress and inflammation, promoting nitric oxide production, and modulating various signaling pathways to protect cardiovascular health and improve cardiac remodeling.
18 papers analyzed
Valsartan is an angiotensin II type 1 (AT1) receptor blocker (ARB) widely used in the treatment of cardiovascular diseases such as hypertension and heart failure. Its primary mechanism involves blocking the AT1 receptor, which plays a crucial role in the renin-angiotensin-aldosterone system (RAAS), leading to vasodilation and reduced blood pressure .
Valsartan has been shown to attenuate cardiac remodeling, a process involving structural and functional changes in the heart, often due to chronic hypertension or heart failure. In a study involving a rabbit model of atrial fibrillation (AF), sacubitril/valsartan was found to reverse atrial and ventricular enlargement, reduce myocardial fibrosis, and decrease AF inducibility. This effect was linked to the inhibition of calcineurin and nuclear factor of activated T-cells (NFAT) signaling pathways, as well as the regulation of calcium ion concentration and ICaL density.
Valsartan exhibits significant anti-inflammatory and antioxidant properties. It reduces reactive oxygen species (ROS) generation and nuclear factor kappa B (NF-κB) activity in mononuclear cells, which are key mediators of inflammation. This reduction in ROS and NF-κB activity leads to decreased levels of pro-inflammatory markers such as C-reactive protein (CRP). Additionally, valsartan has been shown to upregulate heme oxygenase-1 (HO-1), which plays a protective role in vascular health by reducing neointimal hyperplasia in injured arteries.
Valsartan enhances NO production, which is crucial for vascular health. It increases the phosphorylation of endothelial nitric oxide synthase (eNOS) via the Src/PI3K/Akt signaling pathway, leading to elevated NO levels. This mechanism contributes to the vasoprotective effects of valsartan by promoting vasodilation and improving endothelial function .
Recent studies suggest that valsartan has antiglycooxidant properties, which help in reducing protein glycation and oxidation. This effect is comparable to known antioxidants and antiglycation agents, indicating that valsartan can improve redox balance and potentially prevent the development of cardiovascular diseases.
Valsartan also protects against endoplasmic reticulum (ER) stress-induced myocardial apoptosis, particularly in diabetic cardiomyopathy. It downregulates the expression of CHOP and Puma, two critical factors in ER stress-induced apoptosis, thereby reducing cardiac remodeling and cell death.
Valsartan's multifaceted mechanism of action includes blocking the AT1 receptor, reducing inflammation and oxidative stress, enhancing NO production, and protecting against ER stress-induced apoptosis. These combined effects contribute to its efficacy in treating cardiovascular diseases, making it a valuable therapeutic agent in managing conditions like hypertension and heart failure. Further research may continue to uncover additional benefits and mechanisms, solidifying its role in cardiovascular therapy.
Most relevant research papers on this topic